Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Sex Differences in Nociceptin/Orphanin FQ Peptide Receptor-Mediated Pain and Anxiety Symptoms in a Preclinical Model of Post-traumatic Stress Disorder.

Zhang Y, Schalo I, Durand C, Standifer KM.

Front Psychiatry. 2019 Jan 8;9:731. doi: 10.3389/fpsyt.2018.00731. eCollection 2018.

2.

Post-blast treatment with Nociceptin/Orphanin FQ peptide (NOP) receptor antagonist reduces brain injury-induced hypoxia and signaling proteins in vestibulomotor-related brain regions.

Awwad HO, Durand CD, Gonzalez LP, Tompkins P, Zhang Y, Lerner MR, Brackett DJ, Sherry DM, Awasthi V, Standifer KM.

Behav Brain Res. 2018 Mar 15;340:183-194. doi: 10.1016/j.bbr.2016.10.041. Epub 2016 Oct 25.

PMID:
27793733
3.

Blast Overpressure Waves Induce Transient Anxiety and Regional Changes in Cerebral Glucose Metabolism and Delayed Hyperarousal in Rats.

Awwad HO, Gonzalez LP, Tompkins P, Lerner M, Brackett DJ, Awasthi V, Standifer KM.

Front Neurol. 2015 Jun 17;6:132. doi: 10.3389/fneur.2015.00132. eCollection 2015.

4.

Nociceptin/orphanin FQ peptide receptor antagonist JTC-801 reverses pain and anxiety symptoms in a rat model of post-traumatic stress disorder.

Zhang Y, Simpson-Durand CD, Standifer KM.

Br J Pharmacol. 2015 Jan;172(2):571-82. doi: 10.1111/bph.12701. Epub 2014 Jul 1.

5.

Cellular mechanisms of nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor regulation and heterologous regulation by N/OFQ.

Donica CL, Awwad HO, Thakker DR, Standifer KM.

Mol Pharmacol. 2013 May;83(5):907-18. doi: 10.1124/mol.112.084632. Epub 2013 Feb 8. Review.

6.

Increased nociceptive sensitivity and nociceptin/orphanin FQ levels in a rat model of PTSD.

Zhang Y, Gandhi PR, Standifer KM.

Mol Pain. 2012 Oct 20;8:76. doi: 10.1186/1744-8069-8-76.

7.

Sex differences in the Nociceptin/Orphanin FQ system in rat spinal cord following chronic morphine treatment.

Zhang Y, Donica CL, Standifer KM.

Neuropharmacology. 2012 Sep;63(3):427-33. doi: 10.1016/j.neuropharm.2012.04.028. Epub 2012 May 2.

8.

Orphanin FQ/nociceptin activates nuclear factor kappa B.

Donica CL, Ramirez VI, Awwad HO, Zaveri NT, Toll L, Standifer KM.

J Neuroimmune Pharmacol. 2011 Dec;6(4):617-25. doi: 10.1007/s11481-011-9279-2. Epub 2011 May 6.

9.

Methylnaltrexone in the treatment of opioid-induced constipation.

Greenwood-Van Meerveld B, Standifer KM.

Clin Exp Gastroenterol. 2008;1:49-58. Epub 2008 Dec 14.

10.

The presence of beta2-adrenoceptors sensitizes alpha2A-adrenoceptors to desensitization after chronic epinephrine treatment.

Bawa-Khalfe T, Altememi GF, Mandyam CD, Schwarz LA, Eikenburg DC, Standifer KM.

BMC Pharmacol. 2007 Dec 20;7:16.

11.

Extracellular signal-regulated kinase 1/2-mediated transcriptional regulation of G-protein-coupled receptor kinase 3 expression in neuronal cells.

Salim S, Standifer KM, Eikenburg DC.

J Pharmacol Exp Ther. 2007 Apr;321(1):51-9. Epub 2007 Jan 25.

PMID:
17255468
13.

Involvement of G protein-coupled receptor kinase (GRK) 3 and GRK2 in down-regulation of the alpha2B-adrenoceptor.

Desai AN, Salim S, Standifer KM, Eikenburg DC.

J Pharmacol Exp Ther. 2006 Jun;317(3):1027-35. Epub 2006 Mar 13.

PMID:
16533872
14.

Orphanin FQ/nociceptin potentiates [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin-Induced mu-opioid receptor phosphorylation.

Ozsoy HZ, Thakker DR, Standifer KM.

Mol Pharmacol. 2005 Aug;68(2):447-56. Epub 2005 May 12.

PMID:
15890842
15.

Cellular G protein-coupled receptor kinase levels regulate sensitivity of the {alpha}2b-adrenergic receptor to undergo agonist-induced down-regulation.

Desai AN, Standifer KM, Eikenburg DC.

J Pharmacol Exp Ther. 2005 Feb;312(2):767-73. Epub 2004 Sep 29.

PMID:
15456839
16.

Simultaneous alpha2B- and beta2-adrenoceptor activation sensitizes the alpha2B-adrenoceptor for agonist-induced down-regulation.

Desai AN, Standifer KM, Eikenburg DC.

J Pharmacol Exp Ther. 2004 Nov;311(2):794-802. Epub 2004 Jun 10.

PMID:
15192083
17.

Mu-opioid-induced desensitization of opioid receptor-like 1 and mu-opioid receptors: differential intracellular signaling determines receptor sensitivity.

Mandyam CD, Thakker DR, Standifer KM.

J Pharmacol Exp Ther. 2003 Sep;306(3):965-72. Epub 2003 May 15.

PMID:
12750434
18.

Assessing opioid regulation of adenylyl cyclase activity in intact cells.

Thakker DR, Ozsoy HZ, Standifer KM.

Methods Mol Med. 2003;84:29-37. No abstract available.

PMID:
12703314
19.
21.

Orphanin FQ/nociceptin blocks chronic morphine-induced tyrosine hydroxylase upregulation.

Thakker DR, Standifer KM.

Brain Res Mol Brain Res. 2002 Sep 30;105(1-2):38-46.

PMID:
12399106
22.
23.

Synaptic protein expression by regenerating adult photoreceptors.

Yang H, Standifer KM, Sherry DM.

J Comp Neurol. 2002 Feb 11;443(3):275-88.

PMID:
11807837
24.

Vesicle-associated membrane protein isoforms in the tiger salamander retina.

Sherry DM, Yang H, Standifer KM.

J Comp Neurol. 2001 Mar 19;431(4):424-36.

PMID:
11223812
25.

Orphanin FQ/nociceptin and naloxone benzoylhydrazone activate distinct receptors in BE(2)-C human neuroblastoma cells.

Mathis JP, Mandyam CD, Altememi GF, Pasternak GW, Standifer KM.

Neurosci Lett. 2001 Feb 23;299(3):173-6.

PMID:
11165763
26.

Morphine and morphine-6beta-glucuronide-induced feeding are differentially reduced by G-protein alpha-subunit antisense probes in rats.

Silva RM, Rossi GC, Mathis JP, Standifer KM, Pasternak GW, Bodnar RJ.

Brain Res. 2000 Sep 8;876(1-2):62-75.

PMID:
10973594
27.

beta-Funaltrexamine inactivates ORL1 receptors in BE(2)-C human neuroblastoma cells.

Mandyam CD, Altememi GF, Standifer KM.

Eur J Pharmacol. 2000 Aug 18;402(1-2):R1-37.

PMID:
10940375
28.

GABA(A) receptor binding and localization in the tiger salamander retina.

Wang H, Standifer KM, Sherry DM.

Vis Neurosci. 2000 Jan-Feb;17(1):11-21.

PMID:
10750823
29.
30.

3H-morphine-6beta-glucuronide binding in brain membranes and an MOR-1-transfected cell line.

Brown GP, Yang K, Ouerfelli O, Standifer KM, Byrd D, Pasternak GW.

J Pharmacol Exp Ther. 1997 Sep;282(3):1291-7.

PMID:
9316837
31.

G proteins and opioid receptor-mediated signalling.

Standifer KM, Pasternak GW.

Cell Signal. 1997 May-Jun;9(3-4):237-48. Review.

PMID:
9218123
32.

Sigma binding in a human neuroblastoma cell line.

Ryan-Moro J, Chien CC, Standifer KM, Pasternak GW.

Neurochem Res. 1996 Nov;21(11):1309-14.

PMID:
8947921
33.

Synthesis and characterization of substituted benzoylhydrazones of naloxone.

Ciszewska GR, Ginos JA, Charton M, Standifer KM, Brooks AI, Brown GP, Ryan-Moro JP, Berzetei-Gurske I, Toll L, Pasternak GW.

Synapse. 1996 Oct;24(2):193-201.

PMID:
8890461
34.
35.

Characterizing kappa3 opioid receptors with a selective monoclonal antibody.

Brooks AI, Standifer KM, Rossi GC, Mathis JP, Pasternak GW.

Synapse. 1996 Mar;22(3):247-52.

PMID:
9132993
36.

Antisense oligodeoxynucleotides to the cloned delta receptor DOR-1: uptake, stability, and regulation of gene expression.

Standifer KM, Jenab S, Su W, Chien CC, Pan YX, Inturrisi CE, Pasternak GW.

J Neurochem. 1995 Nov;65(5):1981-7.

PMID:
7595481
37.

Mapping of opioid receptors using antisense oligodeoxynucleotides: correlating their molecular biology and pharmacology.

Pasternak GW, Standifer KM.

Trends Pharmacol Sci. 1995 Oct;16(10):344-50. Review.

PMID:
7491712
39.

Demonstration of kappa 3-opioid receptors in the SH-SY5Y human neuroblastoma cell line.

Cheng J, Standifer KM, Tublin PR, Su W, Pasternak GW.

J Neurochem. 1995 Jul;65(1):170-5.

PMID:
7790858
40.

Cloning and functional characterization through antisense mapping of a kappa 3-related opioid receptor.

Pan YX, Cheng J, Xu J, Rossi G, Jacobson E, Ryan-Moro J, Brooks AI, Dean GE, Standifer KM, Pasternak GW.

Mol Pharmacol. 1995 Jun;47(6):1180-8.

PMID:
7603458
41.

TIPP[psi], a highly selective delta ligand.

Visconti LM, Standifer KM, Schiller PW, Pasternak GW.

Neurosci Lett. 1994 Nov 7;181(1-2):47-9.

PMID:
7898768
42.

Biochemical and pharmacological characterization of mu, delta and kappa 3 opioid receptors expressed in BE(2)-C neuroblastoma cells.

Standifer KM, Cheng J, Brooks AI, Honrado CP, Su W, Visconti LM, Biedler JL, Pasternak GW.

J Pharmacol Exp Ther. 1994 Sep;270(3):1246-55.

PMID:
7932177
43.

Selective loss of delta opioid analgesia and binding by antisense oligodeoxynucleotides to a delta opioid receptor.

Standifer KM, Chien CC, Wahlestedt C, Brown GP, Pasternak GW.

Neuron. 1994 Apr;12(4):805-10.

PMID:
8161452
44.

Opioid binding in giant toad and goldfish brain.

Brooks AI, Standifer KM, Cheng J, Ciszewska G, Pasternak GW.

Receptor. 1994 Spring;4(1):55-62.

PMID:
8038707
45.

Modulation of Mu1 opioid binding by magnesium: evidence for multiple receptor conformations.

Standifer KM, Clark JA, Pasternak GW.

J Pharmacol Exp Ther. 1993 Jul;266(1):106-13.

PMID:
8392546
46.

Gender effects and central opioid analgesia.

Kepler KL, Standifer KM, Paul D, Kest B, Pasternak GW, Bodnar RJ.

Pain. 1991 Apr;45(1):87-94.

PMID:
1677751
47.

Affinity labeling of mu and kappa receptors with naloxone benzoylhydrazone.

Standifer KM, Murthy LR, Kinouchi K, Steele L, Pasternak GW.

Mol Pharmacol. 1991 Mar;39(3):290-8.

PMID:
1848652
48.

Reduction by central beta-funaltrexamine of food intake in rats under freely-feeding, deprivation and glucoprivic conditions.

Arjune D, Standifer KM, Pasternak GW, Bodnar RJ.

Brain Res. 1990 Dec 3;535(1):101-9.

PMID:
1963340
49.

Modulation of mu 1, mu 2, and delta opioid binding by divalent cations.

Kinouchi K, Standifer KM, Pasternak GW.

Biochem Pharmacol. 1990 Jul 15;40(2):382-4. No abstract available.

PMID:
2165406
50.

Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite.

Paul D, Standifer KM, Inturrisi CE, Pasternak GW.

J Pharmacol Exp Ther. 1989 Nov;251(2):477-83.

PMID:
2810109

Supplemental Content

Loading ...
Support Center